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RESEARCH ARTICLE
Germline mutations in candidate
predisposition genes in individuals with
cutaneous melanoma and at least two
independent additional primary cancers
Antonia L. Pritchard*, Peter A. Johansson, Vaishnavi Nathan, Madeleine Howlie,
Judith Symmons, Jane M. Palmer, Nicholas K. Hayward
Oncogenomics Group, QIMR Berghofer Medical Research Institute, Brisbane, Australia
* antonia.pritchard@qimrberghofer.edu.au
Abstract
Background
While a number of autosomal dominant and autosomal recessive cancer syndromes have
an associated spectrum of cancers, the prevalence and variety of cancer predisposition
mutations in patients with multiple primary cancers have not been extensively investigated.
An understanding of the variants predisposing to more than one cancer type could improve
patient care, including screening and genetic counselling, as well as advancing the under-
standing of tumour development.
Methods
A cohort of 57 patients ascertained due to their cutaneous melanoma (CM) diagnosis and
with a history of two or more additional non-cutaneous independent primary cancer types
were recruited for this study. Patient blood samples were assessed by whole exome or
whole genome sequencing. We focussed on variants in 525 pre-selected genes, including
65 autosomal dominant and 31 autosomal recessive cancer predisposition genes, 116
genes involved in the DNA repair pathway, and 313 commonly somatically mutated in can-
cer. The same genes were analysed in exome sequence data from 1358 control individuals
collected as part of non-cancer studies (UK10K). The identified variants were classified for
pathogenicity using online databases, literature and in silico prediction tools.
Results
No known pathogenic autosomal dominant or previously described compound heterozy-
gous mutations in autosomal recessive genes were observed in the multiple cancer cohort.
Variants typically found somatically in haematological malignancies (in JAK1, JAK2, SF3B1,
SRSF2, TET2 and TYK2) were present in lymphocyte DNA of patients with multiple primary
cancers, all of whom had a history of haematological malignancy and cutaneous melanoma,
as well as colorectal cancer and/or prostate cancer. Other potentially pathogenic variants
were discovered in BUB1B, POLE2, ROS1 and DNMT3A. Compared to controls, multiple
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cancer cases had significantly more likely damaging mutations (nonsense, frameshift ins/
del) in tumour suppressor and tyrosine kinase genes and higher overall burden of mutations
in all cancer genes.
Conclusions
We identified several pathogenic variants that likely predispose to at least one of the
tumours in patients with multiple cancers. We additionally present evidence that there may
be a higher burden of variants of unknown significance in ‘cancer genes’ in patients with
multiple cancer types. Further screens of this nature need to be carried out to build evidence
to show if the cancers observed in these patients form part of a cancer spectrum associated
with single germline variants in these genes, whether multiple layers of susceptibility exist
(oligogenic or polygenic), or if the occurrence of multiple different cancers is due to random
chance.
Introduction
Cutaneous melanoma (CM) accounts for about 4% of skin cancers, but approximately 75% of
deaths from the disease. CM results from the malignant transformation of melanocytes, the
pigment-producing cells responsible for hair, eye and skin colour. CM risk is heritable and
high penetrance germline mutations in CDKN2A,CDK4, BAP1, MITF, TERT, POT1, ACD,
TERF2IP and POLE have been reported to contribute to CM development in some high den-
sity melanoma families [1, 2]. Additionally, genome-wide association studies (GWAS) have to
date identified 20 low penetrance loci in non-high density familial (‘sporadic’) melanoma
patients [3]. CM has a highly aberrant genome [4], strongly suggesting a role for aberrant
DNA repair mechanisms. Notably, GWAS hits have been proximal to three genes involved
in DNA repair, ATM, also an autosomal recessive cancer gene, (11q22-q23; rs73008229,
genome-wide significance = 1.4x10-12), PARP1 (1q42.12; rs3219090, genome-wide signifi-
cance = 7.1x10-12) and RAD23B (9q31.2; rs10739221, genome-wide significance = 9.6x10-9)
[3]; however the exact mechanisms behind risks associated with these GWAS hits have yet to
be ascertained. Additionally, pathogenic variants in BRCA1 and BRCA2, autosomal dominant
cancer risk genes, both crucial in the process of homologous recombination DNA repair,
increase risks to CM and uveal melanoma (UM), as well as several other cancer types including
breast and ovarian cancer [5, 6]). The susceptibility to CM and UM associated with BRCA1/
BRCA2 is an example of melanotic tumours being part of a spectrum of tumours associated
with well characterised cancer predisposition syndromes. Together, these data suggest a poten-
tial role for aberrations in DNA repair genes in the susceptibility to CM, UM and other
cancers.
Recent evidence has shown an increased burden in pathogenic/probably pathogenic muta-
tions in previously described ‘cancer’ genes (associated with autosomal dominant, autosomal
recessive, cancer predisposition GWAS hits, or somatic driver events) in patients with paediat-
ric cancer, compared to two control populations [7]. A second investigation recently examined
‘cancer predisposition’ mutation burden in a control population, unselected for cancer status.
This study found that 3% of all variants identified were classified as deleterious and that 85%
of all variants identified were of unknown significance; importantly, every individual carried
multiple rare nonsynonymous variants in these genes, with an average of 68 variants/person
(range:49–97) [8].
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In our extensive collection of CM patients, a subset of 57 individuals had 2 or more addi-
tional independent primary tumours. These patients do not have genetic mutations in known
high penetrance CM [1, 2] or UM (BAP1 [9]) genes. The reason for the cancer accumulation
in these individuals is therefore undetermined and could be a due to environmental compo-
nents, random chance, polygenic risk, or rare unidentified high-risk cancer variants. Here, we
hypothesise that mutations in a curated ‘cancer gene’ list and/or DNA repair genes are key ele-
ments to the cancer susceptibility in individuals with three or more primary cancers. We have
therefore undertaken an investigation of 525 ‘cancer’ or DNA repair genes and describe the
prevalence and spectrum of germline variants in this cohort of multiple cancer patients, com-
pared to a control (non-cancer) cohort.
Methods
Study populations
The multiple cancer cases were all ascertained in Australia and were selected from those col-
lected as part of the Q-MEGA project [10] which is a Queensland population-based study
investigating the link between genetics and environment in melanoma development.
Q-MEGA consists of four study samples: The Queensland Study of Childhood Melanoma
(n = 101), The study of Melanoma in Adolescents (n = 298), The Study of Men over 50
(n = 178) and the Queensland Familial Melanoma Project (QFMP; n = 1897) [11]. Detailed
information on personal and family cancer history was ascertained, which was used to identify
individuals with at least three discrete primary cancers (one of which was CM and the other
two were non-cutaneous) and without significant family history of CM; eligible individuals
were those who did not have detectable deleterious mutations in CDKN2A or CDK4 genes.
This resulted in the identification of 57 individuals suitable for this study (S1 Table).
The total UK10K cohort consists of participants originating from 28 studies, broadly split
into four categories 1. Population studies 2. Rare disease studies 3. Obesity studies and 4. Neu-
rodevelopmental studies. Thirteen individual cohorts from across these categories are available
for use as control populations, of which eight consist of unrelated individuals. In this study,
only the UK10K cohorts consisting of unrelated individuals with permission to use as controls
were assessed, which are: hypercholesterolemia (n = 125), thyroid (n = 121), severe insulin
resistance (n = 121), rare neuromuscular diseases (n = 119), neurodevelopment disorders
(n = 175), schizophrenia (n = 389 and n = 232) and autism spectrum disorder (n = 76); total
cohort = 1358.
Ethics and consent
All study participants gave written informed consent for participation. The multiple cancer
cases were collected under ethics approval granted by the Human Research Ethics Committees
of the QIMR Berghofer Medical Research Institute (HREC reference number: HREC/14/
QPAH/495). The UK10K dataset is controlled by the “UK10K Data Access Committee”, who
granted access to download the relevant cohorts under the conditions outlined in the Data
Access Agreement and the Ethical Governance Framework.
Sequencing and bioinformatic analysis
The 57 individuals with multiple cancers included in this study were analysed by WGS or
WES. Sequencing was performed by Macrogen (Korea) on the Illumina Hiseq 2000 platform.
Paired-end reads of 101bp were generated, with mean coverage of 60 to 96X. The BWA align-
ment algorithm was used to map sequence reads to the UCSC human genome reference build
Germline mutations in candidate predisposition genes in individuals with multiple primary cancers
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19 [12]. SNVs were detected using bcftools and SAMtools mpileup with disabled BAQ compu-
tation [13] and indels were detected with pindel [14] and annotated to dbSNP144 by ANNO-
VAR [15]. Variants altering the coding sequence were selected that were present at a frequency
of<1:100 (0.01) in the Kaviar aggregated control population [16]
Selection of cancer predisposition and DNA repair genes
A total of 525 genes were selected for analysis, on the basis of the American College of Medical
Genetics and Genomics (ACMG) gene list [17], the Online Mendelian Inheritance in Man
(OMIM) [18], the LOVD database [19] and the literature [2, 7, 20–23]; S2 Table. This includes
65 autosomal dominant cancer predisposition genes, 31 autosomal recessive cancer predispo-
sition genes, 23 genes encoding tyrosine kinases, 58 tumour suppressor genes, 232 cancer asso-
ciated genes and 116 DNA repair genes.
Validation of variants
The non-silent nucleotide substitution germline variant calls were assessed for read depth, ref-
erence count, alternative count and SNP call quality score. A variant quality score70, alter-
native reads>2 and a ratio of alternative count:reference count0.20 has been established as
the criteria to maximize true variant calls and minimize false positives [21]. Sanger validation
was performed on frameshift mutations in the multiple cancer cohort to ensure the correct
base pairs were called for the in/del.
Interpretation of variants
Variants were assessed using a number of methods in order to identify those that are patho-
genic or potentially pathogenic. This included the assessment of variants present in ClinVar,
ensuring the variant is correct (i.e. some genetic locations have multiple variants, with different
functional consequences) and what level of review status has been established. Variants were
assessed using four in silico tools that predict whether an amino acid alteration affects protein
function: SIFT [24], PolyPhen-2 [25], likelihood ratio test [26] and Mutation Taster [27].
There were instances where a variant was not found / able to be assessed by a given in silico
prediction tool, which are noted in the text where appropriate. Where consistent in silico pre-
diction of deleterious effect of a SNV is present, this is indicative of a potentially damaging
mutation. Curated publicly available germline variant databases were interrogated for evidence
of prior mutation classification. The databases accessed were: LOVD [19] (APC, BRCA1,
BRCA2, CBL, MLH1, MLH3, MSH2, MSH6, MUTYH, PMS2, RB1); UMD [28] (APC, MEN1,
MLH1, MSH2, MSH6); IARC R18 [29] (TP53); ASU [30] (TERT); ARUP [31] (RET); NHGRI
[https://research.nhgri.nih.gov/bic/] (BRCA1, BRCA2). Somatic mutation databases (COS-
MIC [32] and TCGA cBioPortal [33]) were assessed for hotspots that corresponded to germ-
line mutations observed. Finally, OMIM and literature searches (e.g. NCBI PubMed) were
used to examine the functional analyses performed on previously identified variants.
Results
Characteristics of the cohorts
All of the individuals in the multiple cancer patient cohort had histopathologically confirmed
CM and all cancers were registered at the Queensland Cancer Registry. The tumours present
in this cohort are detailed in Fig 1A and the ages at diagnosis of the tumours are shown in Fig
1B and S1 Table. The majority of cancers were diagnosed later in life, but 25% of non-CM and
40% of CM were diagnosed at60 years of age (Fig 1B). The median ages of the 1st diagnosed
Germline mutations in candidate predisposition genes in individuals with multiple primary cancers
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cancer was 61 years, with the 2nd and 3rd cancers at 70 and 78 years, respectively. The UK10K
cohort consists of several independently collected cohorts, with no information available on
cancer in the individuals.
Autosomal dominant genes
Of the 57 individuals with three or more distinct primary tumours, 53 instances of non-silent
mutation were identified from the 63 autosomal dominant cancer predisposition genes at a
Kaviar aggregate population frequency of less than 1:100 (47 missense, 1 splicing, 1 nonsense,
and 4 non-frameshift ins/dels). Of these, 42 variants are present at a Kaviar aggregate popula-
tion frequency of less than 1:2000 (33 missense, 1 splicing, 1 nonsense, and 2 non-frameshift
in/dels); S3 Table. The nonsense mutation (CBL p.E658X) results in the termination of the
protein product 249 amino acids prematurely and the removal of the vital tyrosinases at p. 700,
731 and 774, which are the key phosphorylation sites. It is likely, however, that this truncation
does not result in a traditional oncogenic transformation of the CBL protein. Pathogenic
mutations described to date require a functional tyrosine kinase binding domain (TKB, from
p.51 – 349) and disruption of the α-helix formed between the TKB and RING domains; the
truncating mutation in our cohort (p.Glu658X) does not disrupt this interaction [34]. Addi-
tionally, the RASopathy associated mutations cluster around the RING domain, with described
mutations occurring from p.Q367–R420 [35], which is before the protein disruption described
in our patient. Therefore, while this variant is not part of the known autosomal dominant can-
cer syndrome spectrum, the functional impact of this variant in terms of general cancer sus-
ceptibility is unknown. Of the 47 missense mutations observed, 1 was present in<1:2000 in
the Kaviar population and predicted as damaging by all four in silico prediction algorithms
(BRCA2 p.A75P rs28897701). The BRCA2 p.A75P mutation is, however, not classified as pre-
disposing to breast/ovarian cancer by LOVD [19], or ClinVar. Two additional variants were
present at a frequency of<1:100 individuals in Kaviar and predicted as damaging by in silico
analysis. Additionally, a variant in APC (p.E2445D rs587782127) was predicted as damaging
by the three algorithms able to assess it; this variant is classified as being of unknown signifi-
cance by three submitters in ClinVar and the individual carrying the variant has not had colo-
rectal cancer, commonly associated with APC germline mutations, to date.
The type and frequency of rare germline mutations in AD genes were then assessed in a
control cohort (n = 1358); 1201 occurrences of non-silent mutation were identified from the
65 autosomal dominant cancer predisposition genes at a Kaviar aggregate population fre-
quency of less than 1:100 (1132 missense mutations, 12 splicing, 5 nonsense, 18 frameshift and
34 non-frameshift ins/dels). Of these, 1077 variants are present at a Kaviar aggregate popula-
tion frequency of less than 1:2000 (1005 missense, 15 splicing, 8 nonsense, 20 frameshift and
29 non-frameshift ins/del variants). Two of the nonsense mutations (p.C675X and p.E1013X)
in BRCA1, 7 of the frameshift (p.N162611, p.N302416, p.Q14298, p.L20926, p.K10577
(x2), and p.F154621) in BRCA2 and a single frameshift (p.Q606) in PALB2 would predispose
the carrier to breast/ovarian cancer. Finally of note, a p.Q12X variant in TP53 results in early
protein truncation (full length protein is 394 amino acids long) and would result in Li-Frau-
meni syndrome in the carrier. A total of 109 instances of missense variants of a frequency
Fig 1. The cancer types and age at onset in the individuals with multiple independent primary cancers. A) Pie chart showing the
frequency of cancer types in the total series of individuals with multiple independent primary cancer. All individuals were ascertained in
Australia and were selected from those collected as part of the Q-MEGA project, a Queensland population-based study investigating the
genetics of melanoma development; all individuals therefore presented with a history of cutaneous melanoma (CM) and are not represented
in this figure. B) Age of onset for each of the cancers present in the multiple cancer patients. The dotted line at 60 years of age shows that the
majority of cancers developed later in life. CRC: Colorectal cancer; UM: Uveal melanoma; SCC: Head and Neck Squamous Cell Carcinoma.
https://doi.org/10.1371/journal.pone.0194098.g001
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<1:2000 in the Kaviar population were predicted as damaging by all four prediction algo-
rithms; of these, only one of which has been reported as pathogenic in ClinVar (RET p.I852M
rs377767426 [36]). An additional 11 individuals had missense variants predicted as damaging
by the three algorithms able to assess them, none of which are classified as pathogenic in Clin-
Var (S3 Table).
Autosomal recessive genes
Examination of the autosomal recessive (AR) cancer predisposition gene variants from WES/
WGS in all cohorts can only reveal where an individual has more than one variant in the same
gene, but not whether they are on the same chromosome. In the multiple cancer case cohort,
one individual had two missense variants in the same gene (BRIP1; S3 Table, highlighted yel-
low); neither of these variants were classified as damaging by all four prediction tools. In the
UK10K cohort, 74 individual occurrences of more than one variant in the same AR gene were
observed, covering 14 genes (ATM, BRIP1, ERCC4, ERCC5, FANCA, FANCI, FANCM,
MUTYH,RECQL4, SLCO2A1,WRN and XPC, S3 Table, highlighted yellow). No individual
had deleterious mutations observed more than once in the same gene, nor had more than one
occurrence of a variant classified by ClinVar as pathogenic in the same gene.
It is plausible that heterozygous variant(s) in AR genes could cause a more subtle effect,
such as inducing haploinsufficiency that increases susceptibility to cancer without causing an
overt cancer syndrome. The frequencies of all variants in the AR genes are shown in S1A and
S1B Fig. In the multiple cancer cases, truncating variants were seen in FANCC (p.R484X) and
in FANCF (c.484/485 AG deletion). In the UK10K population, there are truncating mutations
in 61 individuals, in 21 genes, including: ATM, BRIP1,MUTYH,NBN, NTHL1, RAD51C,
RECQL4,WRN, XPC, members of the ERCC gene family (ERCC1, ERCC3, ERCC5) and mem-
bers of the FANC gene family (FANCA, FANCC, FANCD2, FANCF, FANCG, FANCI,
FANCM).
Tumour suppressor genes
Tumour suppressor genes (TSG) play important roles in the control of neoplastic transforma-
tion and several have been discovered to be the source of AD cancer syndromes (such as PTEN
and TP53). Examination of the TSG that are not otherwise classified as AD or AR cancer syn-
drome genes (n = 49) in the multiple cancer cohort revealed 50 missense, 1 nonsense, 2 frame-
shift and 6 non-frameshift in/del variants at a frequency of<1:100 in the Kaviar control
population. At a frequency of<1:2000 individuals in Kaviar controls, there are 26 missense, 1
nonsense, 2 frameshift and 3 non-frameshift in/del variants. Of all the missense mutations,
two variants were predicted as damaging by all tools (PMS1 p.T75I rs61756360 and TNFAIP3
p.R761H rs368859219) and another variant was predicted as damaging by the 3 tools that
could assess it (TET2 p.I1873T rs116519313). None of the observed variants in TSGs have
been classified as pathogenic by ClinVar. The most commonly mutated genes with a frequency
<1:100 in Kaviar controls were CBFA2T3, NOTCH1 and TET2; those with a frequency
<1:2000 are ARID1A, CAMTA1 and TET2. The nonsense variant (p.L737X; rs759242053)
occurred in BUB1B. Variants in this gene can cause the AR disorder mosaic variegated aneu-
ploidy, however, when a single deleterious mutation is present, this can result in a premature
chromatid separation trait (OMIM entry 176430), which can lead to an increased susceptibility
to tumour development. Two variants in TET2 are of note; the first, p.I1873T (rs116519313),
is commonly reported as a somatic mutation (COSMIC ID = COSM41741 in haematopoietic/
lymphocyte cancer x18); this patient had CM, colorectal cancer and mast cell leukaemia as
Germline mutations in candidate predisposition genes in individuals with multiple primary cancers
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distinct primary tumours and the second, an AT deletion at c.4874/4875, causing a frameshift
at p.T1626, is in a patient with myeloproliferative disorder at age 65 years.
As described in S3 Table, in the UK10K cohort, 657 missense, 2 splicing, 14 nonsense, 13
frameshift and 13 non-frameshift variants were observed in TSGs at a frequency of<1:2000 in
the Kaviar control population. Of these, 122 variants were classified as deleterious by all four
prediction algorithms and none were currently classified as deleterious by ClinVar. The most
commonly affected TSG in the UK10K cohort are IGF2R, TET2, ARID1A and NOTCH1 at a
frequency of<1:2000 in Kaviar control population. One of the nonsense mutations observed
was in BUB1B (p.R770X; rs750364303), which as previously described could cause premature
chromatid separation trait. A variant in ASXL1 (p.R693X rs373221034) has been reported to
be somatically mutated 38 times in haematopoietic/lymphoid tissue/28 times in pancreatic
cancer (ID = COSM51388) in the COSMIC database.
Tyrosine kinase genes
Tyrosine kinases are commonly somatically mutated in tumours. Assessment of the location
of variants in these revealed several locations that have been previously reported as somatic
mutations (S3 Table). Of particular note in the multiple cancer case patients is the variant in
JAK2 (p.V617F rs77375493), which is very highly somatically mutated in haematopoietic and
lymphoid tissues (reported over 40,000 times in COSMIC, ID = COSM12600) and has been
reported as a gain of function variant in myeloproliferative disorders [37], as well as acting as
a predisposition variant in the germline [38]. The individual with this variant had myelopro-
liferative disorder at age 44. Additionally of potential functional impact: a frameshift variant
in JAK1 (c.3031insC) in an individual who had a history of CM (n = 2), lymphoma (at 75
years of age) and prostate cancer (at 83 years of age); a frameshift variant in TYK2 (c.1725-
1728delinsTT), in an individual with a history of CM (at 42 years of age), lymphoma and clear
cell renal carcinoma (both at 58 years of age), colorectal cancer (at 63 years of age) and prostate
cancer (at 64 years of age); and a nonsense variant in ROS1 (p.L1209X) in an individual who
had CM (at 63 years of age), stomach cancer (at 67 years of age), colorectal cancer (at 68 years
of age), Merkel cell carcinoma (at 78 years of age) and thyroid cancer (at 79 years of age).
As shown in S3 Table, none of the variants in these kinase genes found in the UK10K con-
trol data have been reported as significantly mutated somatically in any cancer type. There are
five frameshift variants (in ABL1,ABL2 and EGFR) and five nonsense variants (in JAK1, JAK2,
PDGFRB and ROS1) that would result in disruption of the protein product.
‘Other’ cancer genes
The final category of ‘cancer’ genes are those previously reported as playing an important role
in cancer, but do not fit into the tumour suppressor or tyrosine kinase categories (S2 and S3
Tables). In the multiple cancer cases, several interesting variants are revealed, including in
DNMT3A (p.R693H rs147001633 reported 121 times in haematopoietic/lymphoid tissue in
COSMIC, ID = COSM442676), SF3B1 (p.K666N rs377023736 reported 31 times in haemato-
poietic/lymphoid tissue in COSMIC, ID = COSM132937) and SRSF2 p.P95L r751713049
reported 134 times in haematopoietic/lymphoid tissue in COSMIC, ID = COSM146288). The
individual with the DNMT3A p.R693H variant had not had any haematological malignancy
prior to death (at age 89 years), while the individual with the SF3B1 p.K666N variant had
chronic myeloid leukaemia. A second individual, who had CM (at age 76 years), prostate can-
cer (at 86 years) and chronic myeloid leukaemia (at age 88 years), had a novel splice variant,
2bp into the intron after exon 18 of DNMT3A; this variant is of unknown functional conse-
quence. The individual with the SRSF2 p.P95L variant is the same patient with the TET2 p.
Germline mutations in candidate predisposition genes in individuals with multiple primary cancers
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I1873T variant and mast cell leukaemia/colorectal cancer. None of the variants in the multiple
cancer cases have been classified as pathogenic by ClinVar.
In the UK10K cohort, several variants are classified as pathogenic in ClinVar (S3 Table);
however, none of these are associated with cancer predisposition by germline mutation. Two
individuals in the UK10K control cohort had the same variant in DNMT3A (p.R693H) and
two individuals had the same variant in SF3B1 (p.K666N) described in the multiple cancer
cases. Additionally, an individual had the PIK3CA p.H1047L rs121913279 variant, which has
been reported at high frequency in breast (n = 183), large intestine (n = 64) and endometrial
(n = 43) cancers in COSMIC, ID = COSM776 and COSM94987.
DNA repair genes
Many identified cancer predisposition genes encode DNA damage repair molecules; we have
therefore additionally examined variants in genes not previously described as cancer genes,
but which have a direct role in DNA damage repair. In the multiple cancer cases, there were 55
missense, 4 splicing, 6 nonsense, and 3 non-frameshift ins/del variants with a frequency of
<1:100 in the Kaviar control population; of these, 31 missense, 2 splicing, 3 nonsense, and 1
non-frameshift ins/del variants had a frequency of<1:2000. A total of 6 missense variants at a
frequency<1:2000 were predicted as damaging by all four algorithms, of which a single indi-
vidual had two rare variants in WRNIP1 and another had a missense variant in POLE2 (p.
L249I). The individual with two WRNIP missense variants (p.R537W rs145167237 and p.
P615L rs372821009) had early onset cancers (Thyroid cancer at 31, CM at 42 and multifocal
clear cell renal cancer at 58 years of age). Both of these variants are in the DNA-dependent
ATPase and ssDNA annealing domain of the protein, which interacts with DNA polymerase δ,
increasing the initiation frequency of DNA synthesis in response to DNA damage. The mis-
sense variant in POLE2 occurred in an individual who had colorectal cancer at age 59 years.
None of the variants in DNA damage repair molecules were present in either ClinVar or COS-
MIC (at a frequency>5).
In the UK10K population, there were 781 missense, 17 splicing, 24 nonsense, 13 non-
frameshift and 32 frameshift ins/del variants were present at a frequency of<1:2000 in the
Kaviar controls. A total of 108 missense variants at a frequency<1:2000 were predicted as
damaging by all four algorithms. None of these variants were in COSMIC (at a frequency>5).
Two variants were present in ClinVar, both of which have been described in the literature in a
compound heterozygote; the first in APTX in an individual with ataxia-ocular apraxia [39]
and the second in LIG1 in an individual with an autosomal recessive immunodeficiency/DNA
damage hypersensitivity syndrome [40].
Global analysis of variants in cancer and DNA repair genes
The large number of variants of unknown significance in the datasets prompted a global com-
parison of the features of the variants, such as proportions of observed variants in our cohorts
previously observed in the Kaviar control cohort, the frequencies of the types of mutation in
the different gene classifications and the burden of variants present in each individual.
Exploration of the proportion of individuals from each cohort with variants previously
observed in the Kaviar control population was carried out to assess whether there were a
greater proportion of variants never/rarely previously observed in the Kaviar control cohort
(n = 77,301) in the multiple cancer cases, compared to the UK10K population control cohort.
No significant difference in the proportion of those variants observed <0.0005 (i.e. in less than
1:2000 chromosomes) in Kaviar in all genes assessed (Mann-Whitney P = 0.33; S2 Fig), i.e.
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there was not an over-representation of very rare/novel mutations in cancer/DNA repair
genes in multiple cancer patients compared to an unselected cohort of individuals.
Examination of the types of mutation observed in each classification of gene showed that
missense variants (predominantly of unknown significance) comprised the largest proportion
of mutations observed. The frequency of damaging mutations (nonsense, frameshifts) were
comparable between cohorts for autosomal dominant at frequencies of<1:100 (1.92% vs.
1.72%) or<1:2000 (2.6% vs. 2.38%) in Kaviar; S1A and S1B Fig. The frequencies of these dam-
aging mutation types, however, were higher in the multiple cancer cases for genes classified as
tumour suppressors (<1:100: 2.34% vs. 5.00% and<1:2000: 3.59% vs. 8.57%, respectively) and
as tyrosine kinases (<1:100: 2.38% vs. 7.32% and <1:2000: 2.61 vs. 8.69%, respectively); S1A
and S1B Fig.
The numbers of mutations in these genes carried by each individual (i.e. the burden of
mutations) at a frequency of<1:2000 in the Kaviar population was compared between people
in the multiple cancer patient cohort to those in the UK10K cohort. This revealed that a greater
number of multiple cancer cases carried multiple variants in cancer genes (Mann-Whitney
P = 0.0012; Fig 2A) and in all genes combined (Mann-Whitney P = 0.0014), but not the DNA
repair genes alone (Mann-Whitney P = 0.092; Fig 2B), compared to those in the UK10K con-
trol population.
Discussion
There is somewhat anecdotal evidence that CM might be one of the cancer types associated
with syndromes such as Li-Fraumeni Syndrome [41] and breast/ovarian cancer syndrome [6].
The low frequency of germline mutations in TP53 or BRCA1/2, respectively means that statis-
tical evidence supporting these associations is rather weak. Further investigation is clearly
required of CM being part of a previously described cancer syndrome. Accumulating evidence
does however suggest that CM may be part of the ‘long tail’ of cancers which form rare compo-
nents of the full spectrum of tumours associated with well characterised cancer predisposition
syndromes. This study therefore aimed to investigate possible genetic predisposition to cancer
in a cohort of patients with CM plus at least two additional independent primary tumour
types, using a candidate gene approach. These genes were selected based on: a) function as
known cancer predisposition genes (AD and AR), b) encoding tumour suppressors, c) encod-
ing tyrosine kinases or d) DNA repair proteins (proteins of these latter subtypes are frequently
aberrant in cancer) and e) those that are somatically relevant to cancer and not in these previ-
ous categories (‘other cancer genes’). In total, we examined coding region variants in 525
genes extracted from WES or WGS data.
In the AD gene category, there were few mutations of note in the multiple cancer cases.
Given that the method of identification of these cancer cases was via their CM diagnosis and
clinical follow-up, it was unlikely that individuals with an unidentified AD cancer syndrome
would have been detected by our study. It is of interest that in the UK10K data, 2 deleterious
variants were identified in BRCA1 and 7 in BRCA2 (a frequency of 0.15% and 0.52%, respec-
tively); the estimated population frequency of pathogenic BRCA1/2 mutations is 1:800
(0.125%) to 1:1000 (0.1%) per gene, although the prevalence varies between ethnic groups and
geographical areas [42]. A frequency of pathogenic variants in approximately 1:200 individuals
for BRCA2 is therefore higher than might be expected from a population of individuals
selected for non-cancer studies. MSH6 is a mismatch-repair gene involved in hereditary non-
polyposis colorectal cancer [43] and endometrial cancer [44]. In the UK10K cohort, 4 individ-
uals had truncating mutations in MSH6 (0.29%, approximately 1:350), which would cause an
increase in colorectal cancer risk (by 8 times) and in endometrial cancer risk (26 times) more
Germline mutations in candidate predisposition genes in individuals with multiple primary cancers
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than the general population [45] in these individuals. Finally, truncating or previously func-
tionally described deleterious missense mutations were observed in CBL (predisposing to
Noonan syndrome, OMIM ID: 613563), EPCAM (Lynch syndrome/hereditary nonpolyposis
colorectal cancer, OMIM ID: 613244), NF1 (Neurofibromatosis, OMIM ID: 162200), PALB2
(breast cancer, OMIM ID: 114480), TP53 (Li Fraumeni Syndrome, OMIM ID: 151623) and
TSC2 (Tuberous sclerosis type 2, OMIM ID: 613254) in the UK10K control cohort. If we take
these data as indicative of the types of deleterious genetic mutations present in a collection of
individuals collated from non-cancer focused cohorts, it is clear that the multiple cancer
cohort has a significant under-representation of such variants, and therefore no unidentified
underlying cancer syndrome predisposition.
Similarly, we do not uncover a previously unrecognised AR cancer syndrome in our multiple
cancer individuals. These cancer syndromes require homozygous or compound heterozygous
mutations and often have a severe phenotype. It is however plausible that haploinsufficiency
may play a role in increasing cancer susceptibility without causing an overt ablation of protein
function leading to a cancer syndrome. In the UK10K cohort, there were a high number of
truncating mutations in FANCM (n = 7), MUTYH (n = 7), NTHL1 (n = 8) and WRN (n = 8),
suggesting the proteins encoded by these genes can withstand the loss of one functional copy.
In the multiple cancer patients, a nonsense variant in FANCC and a frameshift in FANCF were
observed; three frameshifts were observed in these genes in the UK10 data. To date, no cancer
susceptibility has formally been attributed to a heterozygous variant in an autosomal recessive
cancer syndrome gene.
In the tumour suppressor, tyrosine kinase and ‘other’ categories of genes, several variants
robustly described as somatic events in haematological malignancies were observed. As the
JAK2 p.V617F, TET2 p.I1873T, SF3B1 p.K666N, SRSF2 p.P95L and DNMT3A p.R693H vari-
ants are frequent somatically mutated hotpots in haematological malignancy and have not
been previously reported in the germline, it is plausible that our screen of buffy coat derived
DNA detected somatic mutations. The participant with the JAK2 p.V617F variant previously
had myeloproliferative disorder at age 44, and had their blood drawn for DNA extraction
approximately 20 years later; at their death aged 85 years, had no reported diagnosis of recur-
rent haematological malignancy. The participants with a) the SF3B1 p.K666N and b) SRSF2 p.
P95L/TET2 p.I1873T variants, respectively, both had haematological malignancies diagnosed
in a closer timeframe after blood draw (exact date unknown) and therefore, tumour cells may
have been detected. The variant in DNMT3A observed in haematological malignancies (p.
R693H, as reported in COSMIC), was detected in an individual who had not developed such a
tumour type prior to their death aged 89 years (previous cancers are: CM, prostate cancer and
mesothelioma). While it is a common somatic driver event in haematological malignancy, this
variant has also been described as an acquired event in healthy individuals and is present in
~4% of those over the age of 80 years [46]. It is clear from these findings that future screens of
this nature require additional non-blood cell derived sources of DNA in order to further deter-
mine the true origin of the variants observed in these genes.
Frameshift or splice variants in JAK1, DNMT3A, TET2 and TYK2 all occurred in individu-
als with a history of CM and lymphoma/leukaemia and are not previously described as
Fig 2. Cumulative percentage plots of variant burdens. The numbers of variants present at a frequency of<1:2000 in
Kaviar in each of the gene classification lists (‘cancer’ genes and DNA repair genes) were calculated for each individual in
the multiple cancer patients and the UK10K controls. The cumulative percentage of individuals with a given ‘burden’ of
variants was then calculated and plotted for each cohort. A) The cumulative percentage plots of variant burden for all
‘cancer’ genes in the multiple cancer cases (blue) compared to the UK10K controls (red). B) The cumulative percentage
plots of variant burden for DNA repair genes in the multiple cancer cases (blue) compared to the UK10K controls (red).
https://doi.org/10.1371/journal.pone.0194098.g002
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haematological malignancy hotspots; each of these individuals additionally had prostate and/
or colorectal cancer, suggesting a potential phenotype associated with these variants.
Deleterious mutations in BUB1B are associated with premature chromatid separation,
which can lead to increased susceptibility to cancer as well as to producing autosomal trisomy
offspring, or other issues in conception [47]. A variant in BUB1B (p.L373X) occurred in an
individual with CM, breast cancer and mesothelioma. BUB1B has been reported as being
important in two of these tumours [48, 49], but germline variants have not been reported as
being associated with these cancer types (OMIM ID: 602860). Finally, a truncating variant in
ROS1 (p.L1209X) was present in an individual who had CM, stomach, colorectal, merkel cell
and thyroid cancers; ROS1 has been somatically mutated in gastric and colorectal tumours
[50], as well as spitzoid and acral melanomas [51, 52]; however, germline variants in this gene
have only been associated with myocardial infarction (by GWAS [53]), not cancer.
Whether these variants additionally confer increased risk to the other malignancies in these
individuals (which include cutaneous melanoma, colorectal cancer, clear cell renal carcinoma
and prostate cancer), or there are further genetic predispositions in these individuals leading
to the development of these independent primary tumours is an intriguing question. Also in
these two classifications of genes, the frequency of damaging variants (frameshift in/dels and
nonsense) were higher in the multiple cancer cases at frequencies of<1:100 and<1:2000
compared to the UK10K cohort. It is interesting that while these genes were previously associ-
ated with a specific type of cancer susceptibility, they could also confer risk of other primary
tumour development and form part of a tumour spectrum; our observations therefore add fur-
ther support to the previously observed similar results in prostate cancer [23] and in paediatric
cancers [7] cohorts.
The final category of genes examined were those that encode DNA repair proteins. We
observed a variant in POLE2, which was predicted as damaging by all in silico tools, in a patient
who had colorectal cancer at age 59 years old. Variants in this gene have recently been associ-
ated with the development of colorectal cancer and polyposis [54, 55]. POLE2 is a subunit of
the polymerase epsilon enzyme complex; we have previously demonstrated that a deleterious
variant in another member of this complex, POLE, was associated with cutaneous melanoma
development [56]. There is therefore an indication that variants in POLE and POLE2 might be
associated with susceptibility to multiple cancer types. Also of interest were two variants in
WRNIP1 that were predicted as damaging by all in silico tools, which occurred in the same
individual, who had early onset cancers (thyroid cancer at 31, CM at 42 and multifocal clear
cell renal cancer at 58 years of age. Both of these variants are present in the DNA-dependent
ATPase and ssDNA annealing domain of the protein, which interacts with DNA polymerase δ,
causing an increase in the initiation frequency of DNA synthesis in response to DNA damage.
They are too far apart (1600bp) to infer phase from the sequencing data. There are a large
number of missense (n = 22) and frameshift (n = 4) variants in WRNIP1 in the UK10K cohort,
which could be suggestive of a degree of plasticity in the ability of the protein to withstand
mutation.
The most intriguing implication from our observations is that there is a higher burden of
variants in ‘cancer’ genes in patients with multiple primary cancers than in the control popula-
tion. In the majority, these are missense variants of unknown significance. It is plausible that a
number of rare mutations in different genes can act synergistically or additively together to
increase susceptibility to cancer development. This potential mechanism by which the combi-
nation of variants leads to an increased susceptibility to cancer development is intriguing and
would require very careful dissection and functional assessment, and perhaps with the advent
of Cas9/CRISPR technology, this type of complex genetic manipulation might be more feasible
in the future.
Germline mutations in candidate predisposition genes in individuals with multiple primary cancers
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One of the possible reasons for the increased incidence in second and third cancers in these
individuals may be due to treatment for previous malignancies, rather than a genetic predispo-
sition. Both radiotherapy and chemotherapy have been shown to increase the likelihood of
later development of haematological malignancies at between 5 and 8 years post-treatment.
Close assessment of our data suggests this is likely not a significant confounding factor in these
selected individuals. Firstly, 72% (n = 41) of the cohort had cutaneous melanoma as their first
malignancy, for which treatment is was surgical excision. Of the 16 individuals who had a hae-
matological malignancy, 8 were secondary to the CM, 3 were the first cancer and 5 followed a
non-CM solid tumour (4 years, 10 years, 14 years 18 years and 19 years later); i.e. only one
individual who developed a haematological malignancy falls into the predicted risk window.
Another possibility is that the increased burden in missense variants detected in the DNA
of individuals with multiple primary cancers is as a somatic event as a consequence to the
treatment of their previous tumour(s). Unfortunately, we only have DNA available from the
buffy coat derived from blood cells, so cannot confirm in a second tissue (such as buccal swab)
that variants are truly germline and not somatically acquired due to treatment. Comparison of
the count of germline missense variants at a population frequency of<0.01 in all genes, except
the cancer/DNA repair genes, revealed medians of 281 (interquartile range = 237–297) vs. 274
(interquartile range = 256–299) in the multiple cancer vs. UK10K cohorts, respectively;
p>0.05). These data suggest that if treatment has altered the circulating lymphocyte DNA in
the multiple cancer individuals, the effect in this cohort is subtle.
The UK10K cohort does not have cancer information available for the individuals included,
so their treatment history is unknown. It is clear from the genetic data that there are individu-
als present in the UK10K cohort who have cancer syndromes caused by deleterious mutations
(such as BRCA1 nonsense, BRCA2 frameshift and APC frameshift variants). This does, how-
ever, also indicate that the UK10K cohort is a representative cross-section of the general popu-
lation and therefore any difference between this cohort and the multiple cancer cohort are
potentially important.
It is apparent from this investigation that comprehensive automatic characterisation of
mutations is still not currently feasible with each gene/mutation needing to be considered in
its own right. This is due to several factors. The first of these being the way information is
stored in ClinVar, which is by genomic position rather than by specific base pair alteration. An
example of this is at chr2:47637479, rs63749984, in MSH2. This variant can either be a G>C
transition (p.E205Q) or a G>T transition (p.E205X); it is the truncating mutation that is path-
ogenic (as reviewed by ClinVar panel of experts), while the missense mutation is of unknown
significance (not present in ClinVar). This variant (rs63749984) and chromosomal location
are therefore both currently classified as ‘pathogenic’ by ClinVar and without further scrutiny,
the incorrect conclusion would be reached. A second important factor when establishing path-
ogenicity is the biology of the protein involved. For example, while the truncation observed in
CBL (p.E658X) in the multiple cancer cohort and the frameshift in the UK10K cohort (a 7bp
deletion at p.M222) could be automatically designated as damaging, there is no evidence in the
literature of pathogenicity being conferred by truncation of CBL protein. Instead, oncogenic
transformation requires disruption of the α-helix formed between the TKB and RING
domains and an intact kinase domain. Currently, there is no way to perform high throughput
assessment of such activating mutations, which require functional proof of oncogenic activa-
tion. Finally, it is clear that the predominant mutation type is missense ‘variant of unknown
significance’. While these variants can be assessed using in silico prediction tools for impact on
protein function, in depth experimental work is required in order to provide a more definitive
conclusion about the nature of the mutation [57]. Therefore, high throughput in silico analysis
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of the missense variants is still largely limited to those that have been previously described as
being deleterious.
Conclusion
Given the observations of single pathogenic variants predisposing to multiple tumour types
arising in distinct tissues, such as with BAP1 (uveal melanoma, mesothelioma, meningioma,
clear cell renal cell carcinoma and cholangiocarcinoma [58, 59]), BRCA1 or BRCA2 (breast,
ovarian, uveal melanoma) [60–62], it is plausible that other examples exist that have diverse
effects that have yet to be described. Here, we approached this query with a cohort of patients
who had three independent primary cancers to investigate a series of genes either previously
associated with cancer, or which function in roles similar to those previously described as hav-
ing a role in cancer. We identified a number of variants likely to have caused increased suscep-
tibility to at least one of the primary tumours observed and have additionally shown an
increased burden of mutation in affected individuals. Given the later age of onset of many of
these tumours, it is plausible that these variants, either alone or in combination, do not have
high impact on protein function and instead have more subtle cellular effects. Further investi-
gations of this nature are clearly warranted. Similarly, other rationally selected gene sets could
additionally be interrogated for their contribution to cancer predisposition. Given the increas-
ing availability of germline data from cancer patients, studies such as these should be a
research priority. The implication from this and other recent studies [7, 23] is that there are a
significant number of germline genetic variations in genes known to be associated with cancer
processes in individuals with a wide variety of tumour types.
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